S2Medical AB (S2M) fair value: what the stock is really worth
We calculate from audited financials what S2Medical AB is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jul 17, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch S2Medical AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range kr 0.0024 – kr 0.9915 · the kr 0.0054 price screens below the kr 0.0055 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Follow S2Medical in your weekly email
Every Wednesday you see whether S2Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden.
Show more
S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and Epiprotect, a technology designed to protect and support wound healing by creating an environment for tissue recovery. It also provides Symbiovance, a peptide-based functional skincare; Eyracure, a light-activated peptide technology that repairs damaged hair at the molecular level; and Eiratex, a biosynthetic polymer for wound healing applications. In addition, the company distributes instaQrett; skin substitutes under the EPIPROTECT brand; and BIOPAD, an ivory-white soft sponge. The company was incorporated in 2013 and is headquartered in Linköping, Sweden.
Stock analysis
S2Medical AB (S2M) currently trades at kr 0.0054, while our model-based Fair Value estimate is kr 0.0055, implying the stock looks roughly 0.9% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
S2Medical AB reported revenue of 14.4M SEK in FY2025 versus 7.7M SEK in FY2021, a compound +16.9%/yr. Reported net income was −10.1M SEK in FY2025.
Key figures
Market cap 4.6M SEK (≈ $466K) · P/S ratio 0.30 · EPS (TTM) kr −0.0200 · Net margin −70.3% · Return on equity −70.6% · Return on assets (EBIT) −46.3% · Operating margin −25.5% · Revenue (TTM) 16.1M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 33% below its 52-week high and 121% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 1%, S2M screens cheaper than that median.
Fair Value models
Bear kr 0.0055Fair Value kr 0.0055Bull kr 0.0055
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.9%
Start year 2020 (pandemic). Over 10 years: +25.1% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.1%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−58.8% (2020) → −18.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside+1% · Above median
Profitability
Return on assets−8% · Bottom 25%
Net margin (TTM)−63% · Bottom 25%
Operating margin (TTM)−25% · Bottom 25%
Growth and dividend
Revenue growth9% · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B0.05× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "S2Medical AB Fair Value". https://www.fairvalue-calculator.com/stock/S2M
Frequently asked questions
Is S2Medical AB (S2M) overvalued or undervalued?
As of Jul 17, 2026, our model estimates a fair value of kr 0.0055 versus a price of kr 0.0054, about +1% upside (fairly valued).
What is the fair value of S2M?
Our model-based fair value for S2Medical AB is kr 0.0055 (as of Jul 17, 2026), built from audited fundamentals. The current price: kr 0.0054.
What is the quality score of S2M?
S2Medical AB has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for S2Medical AB (S2M)?
Our model-based price target is the fair value of kr 0.0055 (as of Jul 17, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the S2Medical AB stock forecast for 2026?
Our models put fair value at kr 0.0055, about +1% upside versus a price of kr 0.0054 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of S2Medical AB (S2M)?
S2Medical AB reported trailing-twelve-month revenue of about 16.1M SEK (latest available figure, as of Jul 17, 2026).
What is the intrinsic value of S2Medical AB (S2M)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For S2Medical AB it is kr 0.0055 per share (as of Jul 17, 2026), against a price of kr 0.0054. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is S2Medical AB stock overvalued or undervalued in 2026?
As of Jul 17, 2026, S2M trades below its calculated fair value: price kr 0.0054, fair value kr 0.0055, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of S2M?
No. The price is what the market pays today (kr 0.0054); the fair value is what the company's own numbers justify (kr 0.0055). For S2Medical AB the two are kr 0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is S2Medical AB worth?
The market values S2Medical AB at about 4.6M SEK (market capitalisation, as of Jul 17, 2026). Per share that is kr 0.0054; our models calculate a fair value of kr 0.0055 per share.
How solid is the balance sheet of S2Medical AB (S2M)?
Balance-sheet figures for S2Medical AB (as of Jul 17, 2026): return on equity −70.6%. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is S2M from its 52-week high?
S2Medical AB trades at kr 0.0054, about 33% below its 52-week high of kr 0.0080 and 121% above the low of kr 0.0024 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0055 is for.
Which stocks are comparable to S2Medical AB?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is S2Medical AB stock attractive at the current price?
The data as of Jul 17, 2026: price kr 0.0054, calculated fair value kr 0.0055 (+1%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of S2M calculated?
We run S2Medical AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.0055, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. S2Medical AB currently trades 1 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of S2Medical AB (S2M)?
The closing price on Sep 24, 2026 was kr 0.0054. Our model-based fair value is kr 0.0055, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with S2Medical AB right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of S2Medical AB
How large is the market capitalisation of S2Medical AB (S2M)?
The market capitalisation of S2Medical AB is 4.6M SEK (≈ $466K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of S2Medical AB (S2M)?
The price-to-sales ratio of S2Medical AB is 0.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of S2Medical AB (S2M)?
Earnings per share at S2Medical AB are kr −0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of S2Medical AB (S2M)?
The net margin of S2Medical AB is −70.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of S2Medical AB (S2M)?
The return on equity (ROE) of S2Medical AB is −70.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of S2Medical AB (S2M)?
On an EBIT basis the return on assets of S2Medical AB is −46.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of S2Medical AB (S2M)?
The operating margin of S2Medical AB is −25.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at S2Medical AB (S2M)?
Revenue at S2Medical AB is growing +8.5% versus a year earlier (3y avg +45.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does S2Medical AB (S2M) generate?
The free cash flow of S2Medical AB is −1.3M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does S2Medical AB (S2M) hold?
S2Medical AB holds more cash than debt, 907K SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch S2Medical AB in the live analysis
One click puts S2Medical AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
